KATZUNG'S BASIC AND
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of students about the process of
drug development. Which statement by a student indicates
correct understanding?
A. A medication is approved for routine clinical use after
laboratory testing alone.
B. Clinical trials evaluate safety and effectiveness before a
medication is considered for regulatory approval.
C. Animal studies are sufficient to determine the safest dosage
for all patients.
D. Once approved, medications are no longer monitored for
safety.
Correct Answer: B
Rationale:
Clinical trials in human participants are designed to evaluate a
medication's safety, effectiveness, appropriate dosing, and
adverse effects before regulatory approval. Option A is incorrect
because laboratory testing alone is insufficient. Option C is
incorrect because animal studies cannot fully predict human
responses. Option D is incorrect because post-marketing
surveillance continues after approval to identify uncommon or
delayed adverse effects.
,Question 2
A nurse is reviewing the phases of clinical drug development.
Which phase primarily focuses on determining the medication's
effectiveness in patients with the target disease while
continuing to assess safety?
A. Preclinical testing
B. Early first-in-human studies
C. Controlled therapeutic studies in affected patients
D. Post-marketing surveillance
Correct Answer: C
Rationale:
Controlled therapeutic studies involving patients with the target
condition are intended to evaluate effectiveness while
continuing safety assessment. Preclinical testing occurs before
human studies. Early first-in-human studies primarily evaluate
safety, pharmacokinetics, and dosing. Post-marketing
surveillance occurs after approval to identify rare or long-term
adverse effects.
Question 3
A nurse is caring for a patient who asks why a newly prescribed
medication requires ongoing monitoring even though it has
been approved. What is the nurse's best response?
, A. "Approval guarantees that serious adverse effects cannot
occur."
B. "Monitoring helps identify uncommon adverse effects that
may appear after widespread use."
C. "The medication has not actually been tested before
approval."
D. "Monitoring is only required because insurance companies
request it."
Correct Answer: B
Rationale:
Some adverse effects are too rare to be detected during clinical
trials and become evident only after the medication is used in
larger populations. Approval does not eliminate risk.
Medications undergo extensive testing before approval, and
monitoring is based on patient safety rather than insurance
requirements.
Question 4
A patient enrolled in a clinical trial asks the nurse about
informed consent. Which nursing response is most appropriate?
A. "Signing consent means you cannot withdraw from the
study."
CLINICAL PHARMACOLOGY
16TH EDITION
• AUTHOR(S)TODD W.
VANDERAH
TEST BANK
,Question 1
A nurse is teaching a group of students about the process of
drug development. Which statement by a student indicates
correct understanding?
A. A medication is approved for routine clinical use after
laboratory testing alone.
B. Clinical trials evaluate safety and effectiveness before a
medication is considered for regulatory approval.
C. Animal studies are sufficient to determine the safest dosage
for all patients.
D. Once approved, medications are no longer monitored for
safety.
Correct Answer: B
Rationale:
Clinical trials in human participants are designed to evaluate a
medication's safety, effectiveness, appropriate dosing, and
adverse effects before regulatory approval. Option A is incorrect
because laboratory testing alone is insufficient. Option C is
incorrect because animal studies cannot fully predict human
responses. Option D is incorrect because post-marketing
surveillance continues after approval to identify uncommon or
delayed adverse effects.
,Question 2
A nurse is reviewing the phases of clinical drug development.
Which phase primarily focuses on determining the medication's
effectiveness in patients with the target disease while
continuing to assess safety?
A. Preclinical testing
B. Early first-in-human studies
C. Controlled therapeutic studies in affected patients
D. Post-marketing surveillance
Correct Answer: C
Rationale:
Controlled therapeutic studies involving patients with the target
condition are intended to evaluate effectiveness while
continuing safety assessment. Preclinical testing occurs before
human studies. Early first-in-human studies primarily evaluate
safety, pharmacokinetics, and dosing. Post-marketing
surveillance occurs after approval to identify rare or long-term
adverse effects.
Question 3
A nurse is caring for a patient who asks why a newly prescribed
medication requires ongoing monitoring even though it has
been approved. What is the nurse's best response?
, A. "Approval guarantees that serious adverse effects cannot
occur."
B. "Monitoring helps identify uncommon adverse effects that
may appear after widespread use."
C. "The medication has not actually been tested before
approval."
D. "Monitoring is only required because insurance companies
request it."
Correct Answer: B
Rationale:
Some adverse effects are too rare to be detected during clinical
trials and become evident only after the medication is used in
larger populations. Approval does not eliminate risk.
Medications undergo extensive testing before approval, and
monitoring is based on patient safety rather than insurance
requirements.
Question 4
A patient enrolled in a clinical trial asks the nurse about
informed consent. Which nursing response is most appropriate?
A. "Signing consent means you cannot withdraw from the
study."
